The human genome contains thousands of long non-coding RNAs 1 , but specific biological functions and biochemical mechanisms have been discovered for only about a dozen 2-7 . A specific long non-coding RNA-non-coding RNA activated by DNA damage (NORAD)-has recently been shown to be required for maintaining genomic stability 8 , but its molecular mechanism is unknown. Here we combine RNA antisense purification and quantitative mass spectrometry to identify proteins that directly interact with NORAD in living cells. We show that NORAD interacts with proteins involved in DNA replication and repair in steady-state cells and localizes to the nucleus upon stimulation with replication stress or DNA damage. In particular, NORAD interacts with RBMX, a component of the DNA-damage response, and contains the strongest RBMXbinding site in the transcriptome. We demonstrate that NORAD controls the ability of RBMX to assemble a ribonucleoprotein complex-which we term NORAD-activated ribonucleoprotein complex 1 (NARC1)-that contains the known suppressors of genomic instability topoisomerase I (TOP1), ALYREF and the PRPF19-CDC5L complex. Cells depleted for NORAD or RBMX display an increased frequency of chromosome segregation defects, reduced replication-fork velocity and altered cell-cycle progression-which represent phenotypes that are mechanistically linked to TOP1 and PRPF19-CDC5L function. Expression of NORAD in trans can rescue defects caused by NORAD depletion, but rescue is significantly impaired when the RBMX-binding site in NORAD is deleted. Our results demonstrate that the interaction between NORAD and RBMX is important for NORAD function, and that NORAD is required for the assembly of the previously unknown topoisomerase complex NARC1, which contributes to maintaining genomic stability. In addition, we uncover a previously unknown function for long non-coding RNAs in modulating the ability of an RNA-binding protein to assemble a higher-order ribonucleoprotein complex.
, yet this model has been explored in only a few cases. The mechanism that connects the NORAD lncRNA to chromosomal instability remains unknown.
Two recent studies have reported PUMILIO, a highly abundant cytoplasmic RNA-binding protein with no known role in genomic stability, as the sole NORAD-interacting protein 8, 9 . However, these results were obtained from in vitro mixing of exogenous NORAD fragments with cytoplasmic extracts, which may not accurately represent the protein contacts of NORAD in living cells (Supplementary Note 1) .
To reveal the direct interactions of NORAD with proteins in live cells, we captured and identified NORAD-interacting proteins by combining RNA antisense purification (RAP) with quantitative liquid chromatography-mass spectrometry using isobaric mass tag quantification (RAP MS) (Fig. 1a) . HCT116 colon carcinoma cells were treated with 365-nm light after 4-thiouridine labelling 10 , which covalently crosslinks proteins to RNA but not to other proteins. lncRNAprotein complexes were purified by RNA hybrid selection with antisense oligonucleotides that target NORAD, under denaturing and reducing conditions at high temperature to minimize the copurification of indirectly bound proteins 2 (Fig. 1a) . To identify specific interactors with NORAD, we quantitatively compared the resulting proteins to those captured in purifications with antisense oligonucleotides that target the well-characterized 'RNA component of mitochondrial RNA processing endoribonuclease' (RMRP), which is not expected to interact with the same proteins as NORAD
11
. We analysed biological replicate purifications in a single 4-plex iTRAQ cassette, quantifying 1,361 proteins that each had more than two unique peptides (Fig. 1b) . The control purification captured about 85% of RMRP transcripts (Extended Data Fig. 1 ) and enriched the target RNA approximately 550-fold versus input RNA. We found 12 strongly enriched proteins (mean log 2 (iTRAQ ratio (NORAD/RMRP)) < −1.6, P < 0.05, moderated t-test) (Fig. 1c) , including 8 of the 10 known core components of the RMRP complex 11 and one previously identified candidate rRNAand/or tRNA-processing factor 12 .
We then analysed NORAD antisense purifications. Experiments captured 82% of endogenous NORAD (Extended Data Fig. 1 ) (about 80-fold enrichment versus input RNA). We reproducibly identified 45 proteins that met our enrichment criteria (mean log 2 (iTRAQ ratio (NORAD/RMRP)) > 1.6, P < 0.05, moderated t-test) (Fig. 1b) . This set of proteins is highly specific to NORAD, in that 41 out of the 45 proteins (Fig. 1c) were not among 219 promiscuous binders (Supplementary Note 3). The RNA-binding protein PUMILIO2 (PUM2) was indeed present in our NORAD interactome, but it ranked 185th out of the 265 proteins we detected (mean log 2 (iTRAQ ratio (NORAD/ RMRP)) > 0.5) and did not meet our cut-off for strongly enriched proteins.
Notably, many of the 41 NORAD-interacting proteins have key roles in nuclear processes such as DNA unwinding, replication and repair (including PURA, PURB, TAF15, ALYREF, SFPQ, SRSF1, RBM14, DDX17, RBMX and its retrogene RBMXL1). Twenty-nine (71%) of the forty-one proteins localize to the nucleus, nucleoplasm or chromatin, whereas only two (5%) localize exclusively to the cytoplasm (Fig. 1d) . The interactome thus points towards an important nuclear function of NORAD.
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Given the overrepresentation of nuclear proteins, we used singlemolecule RNA fluorescent in situ hybridization (smRNA FISH) to assess the subcellular localization of NORAD in intact cells. In contrast to previous reports that characterized NORAD as being located exclusively in the cytoplasm 8 , we found that on average 40-50% of NORAD transcripts in HCT116 cells reside in the nucleus (Fig. 2a and Extended Data Fig. 2a, b) . We confirmed the nuclear localization by subcellular fractionation and quantitative PCR with reverse transcription (RT-qPCR) (Extended Data Fig. 2c, d) . Notably, when cells were challenged with DNA damage and replication stress, NORAD was upregulated (Extended Data Fig. 2e ) and its nuclear localization increased markedly (to about 85%), whereas the localization patterns of control RNAs were unaffected (Fig. 2a, b) . Given this shift in localization, we performed RAP experiments with and without DNA damage to confirm that the interactions of NORAD with several candidate binders also occur under conditions of DNA damage (Extended Data Fig. 2f, g ).
Among the NORAD-interacting proteins, we focused on RBMX, the knockdown phenotype of which (impaired DNA damage repair 13 and premature sister-chromatid separation 14 ) is closely related to the previously reported NORAD knockout phenotype 8 . To explore this connection, we quantified the frequency of chromosome-segregation defects in response to depletion of NORAD or RBMX by imaging mitotic cells. We achieved >90% reduction in NORAD expression (estimated by RT-qPCR, RNA-sequencing and smRNA FISH) by CRISPR interference (KRAB-dCas9) targeted to the NORAD promoter ( Fig. 2a and Extended Data Fig. 3a, b) . For both wild-type and knockdown cells, we imaged 100 anaphase nuclei and calculated the frequency of DAPIpositive anaphase bridges. Consistent with previous reports 8 , NORAD depletion caused a significant increase (2.2-fold) in segregation defects ( Fig. 2c, d ). Importantly, these defects were rescued by expression of full-length NORAD in trans (Fig. 2d) , indicating that the defects are dependent on the NORAD RNA. Depletion of RBMX (Extended Data Fig. 3a ) caused a comparable increase (2.6-fold) in the frequency of anaphase bridges (Fig. 2d) . By contrast, depletion of the cytoplasmic protein PUM2 (Extended Data Fig. 3a ) caused no substantial increase in segregation defects (Extended Data Fig. 3c ). We reasoned that the interaction between NORAD and RBMX may hold important mechanistic insights into NORAD function.
To explore this interaction, we mapped RBMX-binding sites on NORAD by crosslinking and immunoprecipitation (CLIP). We covalently coupled proteins to RNA using ultraviolet crosslinking 10 and immunopurified RBMX with a specific antibody. We isolated and sequenced RNA crosslinked to RBMX. RBMX displays unusually strong and specific binding to the 5′ end of NORAD (Fig. 2e) . The RBMX-binding site in NORAD extends over more than 800 nucleotides and covers about 15% of NORAD-making it eight times larger than the majority of RBMX-binding sites (Extended Data Fig. 3d ) and the strongest RBMX-binding region in the transcriptome (Fig. 2f ). This unusual binding pattern suggests that NORAD serves as a high-affinity binding target for RBMX and contains many RBMX-binding sites. A multiple sequence alignment of NORAD transcripts, which was assembled de novo from RNA-sequencing data from 11 mammalian species (Extended Data Fig. 3e ), suggests that the RBMX-binding region in NORAD is transcribed and conserved throughout mammalian evolution. Next, we performed CLIP for three additional RNA-binding proteins and showed that the RBMX-binding region does not bind PUMILIO, FUBP1 or FUBP3 (Extended Data Fig. 3f ).
To confirm that the NORAD-RBMX interaction occurs in the nucleus, we performed RBMX RNA immunoprecipitation (RIP) in nuclear and cytoplasmic extracts and showed that over 99% of the total RBMX RIP signal is indeed nuclear (Extended Data Fig. 3g ). Consistent with this result, immunofluorescence microscopy suggests that RBMX localizes exclusively to the nucleus (Extended Data Fig. 3h ). Finally, depletion of RBMX did not affect subcellular localization of NORAD (Extended Data Fig. 3i ).
We speculated that NORAD might use its large RBMX-binding site to assemble a ribonucleoprotein complex. To examine the role of NORAD in such a complex, we sought to identify proteins that bind RBMX and determine whether their interaction with RBMX was dependent on NORAD. We performed co-immunoprecipitation and mass spectrometry (co-IP MS) experiments and compared the quantitative enrichment of RBMX-interacting proteins in cells with and without NORAD knockdown (Fig. 3a) . Importantly, we used a nonspecific RNA and DNA nuclease (benzonase) to ensure that RBMX-binding is direct, rather than being mediated by RNA.
Among the top 11 proteins that bound to RBMX only in the presence of NORAD, 7 are linked to DNA replication or repair (Fig. 3b) .
Six of these proteins (TOP1, TOP1MT, PRPF19, CDC5L, BCAS2 and MEPCE) were not detected in NORAD RAP MS data or were not among the top 200 enriched proteins, which suggests that they bind directly to RBMX and do not interact strongly with NORAD (Extended Data Fig. 4a ). We further confirmed by western blot the absence of TOP1 in NORAD antisense purifications (Extended Data Fig. 4b ) and showed that levels of TOP1, RBMX, PRPF19 and CDC5L proteins 
were not changed upon NORAD depletion (Extended Data Fig. 4c ). PRPF19, CDC5L and BCAS2, together with PLRG1, make up the core of the human PRPF19-CDC5L complex, and both PRPF19-CDC5L and TOP1 have important roles in DNA replication and genomic stability, as previously reviewed 15, 16 . TOP1 suppresses genome instability by preventing interference between replication and transcription
17
. This involves relieving torsional stress in DNA (that is, supercoiling) and suppressing the accumulation of RNA-DNA hybrids (R-loops) 18 . Both R-loops and supercoiled DNA impair replication-fork progression and can lead to genomic instability 17, 19 . Stalled replication forks activate the DNA-damage response though ATR signalling. CDC5L binds and activates ATR
20
, and the E3 ligase PRPF19 ubiquitylates RPA, enhancing ATRIP-ATR recruitment to stalled replications forks 21 . The precise roles of the remaining two NORAD-dependent RBMX interactors in maintaining genomic stability are less well understood. MEPCE binds to the 5′ cap of 7SK 22 and was reported in several studies that aimed to identify proteins involved in the DNA damage response 13, 23 ; however, its exact function in this process remains unknown. Unlike the six proteins above that were not found by RAP to interact strongly with NORAD, a seventh protein-ALYREF-was identified as a strong NORAD binder. ALYREF is part of the human TREX complex and interacts with the 5′ end of many RNAs, including NORAD (Extended Data Fig. 4d ), to facilitate RNA export from the nucleus 24 . ALYREF contributes to genomic stability by suppressing R-loops 24 , as does TOP1. We performed reciprocal co-IP and western blots to confirm that TOP1, ALYREF and CDC5L interact with RBMX and also contact each other (Extended Data Fig. 4e ), suggesting that these proteins may constitute a complex. To test whether such a complex exists, we generated cell lines that express epitope-tagged RBMX and performed co-IP experiments (using benzonase to digest unprotected RNA and DNA) followed by native elution and size-exclusion chromatography. Western blot analysis of size-fractionated co-IP samples showed that RBMX, Table 5 ). Fraction 6 and fraction 20 were used for RNA sequencing. Western blots are representative of one experiment; three independent experiments were performed. SEC, size-exclusion chromatography. d, Proximity ligation assay for RBMX and TOP1. Two different antibody pairs were used. Centre lines, medians; box limits, 25th and 75th percentiles; whiskers, 5th and 95th percentiles; dots, outliers. ****P < 0.0001, ***P < 0.001, NS, not significant, two-tailed Mann-Whitney U test. Sample size antibody pair 1: RBMX WT, n = 102; RBMX KD, n = 193; NORAD WT, n = 521; NORAD KD, n = 559; rescue full length, n = 176; rescue 5P(5′ RBMX-binding site) deletion, n = 171. Sample size antibody pair 2: NORAD WT, n = 209; NORAD KD, n = 232; rescue full length n = 211; rescue 5P deletion, n = 290. Representative images are shown. Scale bar, 20 μm. Values are mean ± standard deviation (NORAD, n = 4, NORAD rescue, n = 2, RBMX, n = 3). ****P < 0.0001, ***P < 0.001, **P < 0.01, two-tailed Student's t-test. e, RBMX CLIP data plotted across NORAD RNA. SM input, size-matched input for proteins migrating at the same molecular weight range as RBMX. MACS2-identified RBMX peak is shown. f, CLIP signal for all RBMX peaks enriched over SM input in two biological replicates. 
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TOP1 and PRPF19 are part of a 700-1,000-kDa complex ( Fig. 3c and Extended Data Fig. 4f ). The majority of TOP1 in this complex displays an approximately 50-kDa size shift, consistent with a known SUMO-1 modification of TOP1 proteins that are associated with transcriptionally active or replicating chromatin
25
. Mass spectrometry confirmed that-in addition to RBMX, TOP1 and PRPF19-RBMXL1, which is encoded by an RBMX retrogene, is a component of this complex (Fig. 3c) . Finally, we speculated that this complex protects NORAD from benzonase digestion. We constructed sequencing libraries using RNA extracted from various size-exclusion chromatography fractions. Notably, RNA footprints that matched the previously identified RBMXbinding site in NORAD were present only in fractions that contained the complex (Fig. 3c ). These data demonstrate that NORAD is a physical part of the captured complex.
We next used proximity ligation assays to show that the RBMX-TOP1 interaction occurs in the nucleus, is disrupted by NORAD depletion and is rescued by re-introducing full-length NORAD into NORAD-depleted cells ( Fig. 3d and Extended Data Fig. 4g ). Importantly, rescue is strongly impaired if the rescue construct lacks the RBMX-binding region ( Fig. 3d and Extended Data Fig. 4g ).
Our results indicate that NORAD modulates the ability of RBMX to interact with other proteins that appear not to bind NORAD directlynamely, TOP1 and the core PRPF19-CDC5L complex. Given the distinct molecular composition of this NORAD-dependent RBMX complex and the functional importance of its components, we name it NORAD-activated ribonucleoprotein complex 1 (NARC1).
Many NARC1 components have prominent roles in maintaining genomic stability. Although individual components such as RBMX or PRPF19 have been reported to contribute to mRNA splicing 13, 16 , we did not observe global changes in mRNA splicing upon NORAD depletion in HCT116 cells (Extended Data Fig. 5a ). In other cell types, RBMX and CDC5L can influence the expression of BRCA2 and BRCA1 13, 26 . However, BRCA1 and BRCA2 were not among differentially expressed genes (Supplementary Table 7 ) and their proteins levels were not noticeably different in NORAD-depleted and normal HCT116 cells (Extended Data Fig. 4c ).
Given the essential role of NORAD in assembling NARC1, we speculated that NORAD depletion may cause a TOP1-related phenotype and directly or indirectly alter DNA replication, which can lead to chromosome segregation defects and genomic instability 27, 28 . To assess the functional consequence of NORAD depletion on replication, we used the DNA combing technique and measured replication-fork velocity at the single-molecule level. Analysis of over 250 replication forks in wild-type and knockdown cells confirmed that NORAD and RBMX depletion significantly reduced replication-fork velocity (Fig. 4a) ; the observed effect-size was comparable to previously published TOP1 knockdown data 18 . Thus, NORAD may directly or indirectly affect DNA replication even in the absence of additional DNA damage stimulus.
We tested whether NORAD depletion also affects cell-cycle progression. We labelled newly synthesized DNA with 5-ethynyl-2′-deoxyuridine (EdU) and measured EdU incorporation and total DNA content by fluorescence-activated cell sorting. We observed a clear decrease in S phase accompanied by increased G1 phase in NORAD-, RBMXand TOP1-depleted cells (Fig. 4b, . Consistent with these findings, impaired replication-fork progression has been linked to chromosome mis-segregation 28 (as observed in NORAD and RBMX knockdown cells), which in turn can trigger a cell-cycle arrest in the subsequent G1 phase 29 . Importantly, a G1 arrest alone cannot explain the reduction in replication-fork velocity observed above. We next examined whether the NORAD-RBMX interaction is important for this effect on cell-cycle progression. Expression of full-length NORAD in trans was sufficient to rescue cell-cycle defects in NORAD-knockdown cells (Fig. 4b and Extended Data Fig. 5b, e) . By contrast, a NORAD construct that lacks the RBMX-binding site decreased S phase and increased G2/M phase; this contrasts with NORAD knockdown and may point towards an altered molecular function of truncated NORAD ( Fig. 4b and Extended Data Fig. 5b, e) . Deletion of the RBMX-binding site may therefore act as a dominant negative alteration, which indicates that the RBMX-binding region is required for correct NORAD function.
Our results link the known function of members of the NARC1 complex (particularly TOP1) in preventing replication stress and genome instability 16, 18, 19, 27 to the role of NORAD in suppressing aneuploidy. Importantly, we demonstrate that the RBMX-binding region in NORAD contributes to NORAD function, presumably by promoting NARC1 assembly.
It has widely been suggested that lncRNAs participate in assembling groups of proteins, but lncRNA-protein complexes have been fully characterized for only a few lncRNAs; these include XIST 2 , TERC 3 , NEAT1 4 , MALAT1 5 and HOTAIR 6 . Our results demonstrate that NORAD is essential for the assembly of the ribonucleoprotein complex NARC1, which physically links proteins known to be involved in DNA replication or repair but not known to act together. We suggest a model in which depletion of NORAD or deletion of its RBMX-binding site disrupts NARC1, which alters replication-fork velocity and impairs Tables 8-10 ). Centre lines, medians; box limits, 25th and 75th percentiles; whiskers, 5th and 95th percentiles; dots, outliers. ****P < 0.0001, two-tailed Mann-Whitney U test. Sample size: NORAD WT, n = 280; NORAD KD, n = 428; RBMX WT, n = 438; RBMX KD, n = 296. b, Cell-cycle analysis by flow cytometry. CRISPR interference was used to deplete RBMX and NORAD (n = 4; Supplementary Table 11) . Fluorescence-activated cell sorting histograms are shown in Extended Data Fig. 5e . c, As in b, but for TOP1. RNA interference was used to deplete TOP1 (n = 6; Supplementary Table 12) . Fluorescence-activated cell sorting histograms are shown in Extended Data Fig. 5f . Values are mean ± 95% confidence interval. ****P < 0.0001, ***P < 0.001, *P < 0.05, NS, not significant, two-tailed Welch's t-test. d, Model illustrating NORAD function. Letter reSeArCH cell-cycle progression. It is tempting to speculate that altered DNA replication causes cells to accumulate the observed chromosome segregation defects, a known cause of genomic instability and aneuploidy 28, 29 ( Fig. 4d ). While our data demonstrates a central role of NARC1 in the NORAD phenotype, other proteins or complexes may contribute to additional aspects of NORAD function.
The precise mechanism or mechanisms by which NORAD promotes NARC1 assembly remain to be elucidated but might include (1) inducing a conformational change in RBMX, (2) recruiting a large number of RBMX molecules to its 5′ end to create a protein interaction scaffold or (3) using other direct interactions to bring NARC1 members into close proximity. RBMX encodes a large low-complexity domain that can self-assemble and undergo phase separation in vitro 30 . Binding of RBMX to NORAD may nucleate the formation of higher-order RBMX assemblies that facilitate binding of other proteins that contain a low-complexity domain.
In addition to these structural features, NORAD has unusual functional features in that NORAD localization to the nucleus can be triggered by DNA damage, which may allow cells to rapidly assemble NARC1 or to re-localize pre-assembled complexes without the need for additional protein synthesis.
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MEthodS
No statistical methods were used to predetermine sample size. The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment. Tissue culture. We maintained HCT116 cells (ATCC) in McCoy's 5A (Thermo Fisher Scientific) with 10% heat-inactivated FBS (HIFBS, Thermo Fisher Scientific), 1 mM sodium pyruvate, 2mM l-glutamine, and 100 units/ml streptomycin and 100 mg/ml penicillin. Cells were grown at 37 °C and 5% CO 2 atmosphere. Lentivirus production. We plated 700,000 HEK293T cells in 6-well tissue culture plates and grew them for 24 h before transfecting with 1 μg dVPR, 300 ng VSVG, and 1.2 μg transfer plasmid using FuGene HD (Promega). Sixteen hours after transfection we changed the medium to DMEM with 20% HIFBS. At 48 h post-transfection, we collected viral supernatants and filtered them through a 0.45 μM syringe filter before use. Generation of CRISPR interference cell lines. We generated inducible CRISPR interference (CRISPRi) cell lines by transducing HCT116 cells with a construct expressing rtTA linked by IRES to a neomycin resistance cassette expressed from an EF1α promoter (ClonTech) and selecting with 200 μg/ml G418 (Thermo Fisher Scientific). Next, rtTA-expressing HCT116 cells were transduced with a previously described KRAB-dCas9 construct linked by IRES to BFP 31 . We selected for cells expressing BFP by fluorescence-activated cell sorting. Inducible NORAD, RBMX and PUM2 knockdown cell lines were generated by transducing stable CRISPRi lines with sgRNAs (expressed from a previously described sgOpti backbone 31 ) and selecting with 1 μg/ml puromycin. RAP MS. To capture endogenous NORAD transcripts, we designed and synthesized 5′ biotinylated 90-mer DNA oligonucleotides (Integrated DNA Technologies) antisense to the target RNA sequence. We used 26 probes that covered the entire NORAD sequence, with the exception of regions that matched to other transcripts or genomic regions as previously described 32 . For NORAD and RMRP antisense purifications we grew 500 million HCT116 cells per RNA. We supplemented cell culture medium with a final concentration of 200 μM 4-thiouridine and grew cells for 8 h before crosslinking. Cells were washed once with PBS and then crosslinked on ice using 0.8 J/cm 2 of 365-nm ultraviolet light in a Stratalinker (Stratagene). Cells were then scraped from culture dishes, washed once with PBS, pelleted by centrifugation at 500g for 5 min and flash-frozen in liquid nitrogen for storage at −80 °C. Preparation of total cell lysates was performed as previously described 2 . For antisense purification of crosslinked protein-RNA complexes we included the following modifications to the previously described procedure: all buffers were pre-heated to 55 °C. We used 50 μg pooled antisense probes for 500 million lysed cells. For pre-clear of lysates and capture of RNA/DNA hybrids we used 5 ml streptavidin Dynabeads MyOne C1 magnetic beads (Thermo Fisher Scientific) for 500 million cells. Elution of captured proteins from streptavidin beads was achieved by digesting nucleic acids using 250 U of benzonase (Millipore), 25 U RNase A and 1000 U RNase T1 (Thermo Fisher Scientific) for 8 h at 37 °C. Trichloroacetic acid-precipitated proteins were reconstituted in 8 M urea and 50 mM Tris-HCl pH 7.8 and stored at −20 °C until processing for mass spectrometry. Protein digestion for RAP MS. RAP-captured proteins were resuspended in 40 μl of digestion buffer (8 M urea, 50 mM Tris-HCl pH 7.8), reduced (1 μl of 160 mM DTT, 30 min, room temperature) and alkylated (1.6 μl of 250 mM IAA, 45 min, dark, room temperature), followed by a 2 h Lys-c digestion (0.1 μg per sample) at room temperature. Next, the samples were diluted with 120 μl of 100 mM Tris-HCl pH 7.8 to a final concentration of <2 M urea, and 0.5 μg of trypsin was added for overnight digestion at room temperature with agitation. Samples were quenched with 8.5 μl of formic acid and desalted on 4-punch STAGETips as previously described 33 . iTRAQ labelling of peptides and BRP fractionation for RAP MS. Desalted peptides were labelled with iTRAQ4 34 reagent according to the manufacturer's instructions (AB Sciex). Peptides were dissolved in 30 μl of 50 mM triethylamonium bicarbonate (TEAB) pH 8.5 and labelling reagent was added in 70 μl of ethanol. Samples were incubated with labelling reagent for 1 h with agitation, and the reaction was quenched with 5 μl of 1 M Tris-HCl pH 7.8. Differentially labelled peptides were subsequently mixed and prepared for BRP fractionation on 50 mg SepPak columns according to the following protocol: cartridges were prepared for desalting by equilibrating with methanol, 50% acetonitrile (ACN), 1% formic acid and 3 washes with 0.1% TFA. Samples were loaded on to the cartridge and washed 3 times with 1% formic acid. A pH switch was performed before the collection of BRP fractions with 5 mM ammonium formate at pH 10. BRP fractions were collected at the following ACN concentrations: 10% ACN in 5 mM ammonium formate; 15% ACN in 5 mM ammonium formate; 20% ACN in 5 mM ammonium formate; 30% ACN in 5 mM ammonium formate; 40% ACN in 5 mM ammonium formate; and 50% ACN in 5 mM ammonium formate. Co-immunoprecipitation and MS. To capture RBMX-interacting proteins, we grew 15 million inducible CRISPRi cells with stably integrated NORAD sgRNAs for each immunoprecipitation experiment. For NORAD depletion samples, we induced knockdown by supplementing cell culture medium with 0.5 μg/ml doxycycline for 72 h, while NORAD wild-type samples were grown without doxycycline. Cells were washed in PBS, trypsinized and collected by centrifugation. Cell pellets were washed twice with ice-cold PBS and cell numbers were counted and normalized between knockdown and wild-type samples. Fresh cell pellets containing 15 million cells were lysed in 375 μl co-IP lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP40, 0.1% sodium deoxycholate, and Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific)). Lysates were incubated on ice for 30 min and mixed by pipetting every 5-10 min to enhance nuclear lysis. Lysates were cleared by centrifugation at 14,000g for 10 min at 4 °C and insoluble material was removed. We pre-cleared lysates by incubating with 50 μl protein A magnetic beads (Thermo Fisher Scientific) for 30 min at 4 °C. Meanwhile, 900 ng RBMX antibody (Cell Signaling #14794) was pre-coupled to 50 μl protein A beads for 45 min at room temperature. We determined the total protein concentration in pre-cleared lysates by BCA assay in triplicates and normalized all samples to contain exactly 2.5 mg total protein. To non-specifically digest all DNA and RNA, we added 50 U benzonase and 1 mM MgCl 2 to all lysates. Free RBMX antibody was removed from magnetic beads and benzonase-treated lysates were added to beads and incubated overnight at 4 °C. The next day, supernatant was removed and beads were washed twice in 50 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.05% NP40, followed by two washes in 50 mM Tris-HCl pH 7.5 and 150 mM NaCl. After the last wash, beads were overlaid with 10 μl PBS and immediately subjected to sample preparation for mass spectrometry and TMT labelling. On-bead protein digestion for co-IP MS. Following immunoprecipitation, washed beads were resuspended in 90 μl of digestion buffer (2 M urea, 50 mM Tris-HCl pH 7.8, 2 mM DTT, 0.005 μg/ml sequencing-grade trypsin) and incubated for 1 h with agitation at 700 rpm. The supernatant was removed and placed in a fresh tube. Beads were washed two times with 60 μl of 2 M urea in 150 mM Tris-HCl pH 7.8, and washes were combined with the supernatant. This procedure was repeated twice to ensure complete removal of proteins from the beads. Supernatants were combined and proteins were reduced (3.5 μl of 500 mM DTT, 30 min, room temperature) and alkylated (9 μl of IAA, 45 min, room temperature, dark), before digestion with 4 μg of trypsin overnight at room temperature with agitation. Samples were acidified (1% formic acid) and desalted on Waters 10 mg Oasis HLB cartridges. TMT labelling of peptides and BRP Fractionation for co-IP MS. Desalted peptides were labelled with TMT6 reagent according to the manufacturer's instructions (Thermo Fisher Scientific). Peptides were dissolved in 25 μl of HEPES pH 8.5 and 0.2 mg of TMT labelling reagent was added to each sample in 10 μl of ACN. Samples were incubated with labelling reagent for 1 h with agitation. Next, the reaction was quenched with 2 μl of 5% hydroxylamine. Differentially labelled peptides were subsequently mixed and prepared for BRP fractionation on 50 mg SepPak columns according to the following protocol: cartridges were prepared for desalting by equilibrating with methanol, 50% ACN, 1% formic acid and 3 washes with 0.1% TFA. Samples were loaded on to the cartridge and washed 3 times with 1% formic acid. A pH switch was performed with 5 mM ammonium formate at pH 10, collected and run as fraction 1. Subsequent fractions were collected at the following ACN concentrations: 10% ACN in 5 mM ammonium formate; 15% ACN in 5 mM ammonium formate; 20% ACN in 5 mM ammonium formate; 30% ACN in 5 mM ammonium formate; 40% ACN in 5 mM ammonium formate; and 50% ACN in 5 mM ammonium formate.
LC-MS/MS Analysis (RAP MS and co-IP MS).
Reconstituted peptides were injected onto a capillary column (Picofrit with 10-μm tip opening, 75-μm diameter, New Objective) packed in-house with 20 cm C18 silica material (1.9 μm ReproSilPur C18-AQ medium, Dr Maisch GmbH), and separated on an online nanoflow EASY-nLC 1000 UHPLC system (Thermo Fisher Scientific). Columns were heated to 50 °C in column heater sleeves (Phoenix-ST) to reduce back-pressure during the gradient. RAP MS experiments. Peptides were separated at a flow rate of 200 nl/min with a linear 120-min gradient from 100% solvent A (3% ACN, 0.1% formic acid) to 35% solvent B (90% ACN, 0.1% formic acid) for 82 min, followed by a 3-min linear increase from 35 to 90% B with a 5-min hold at 60% B before increasing to 90% B for 3 min and holding for 20 min, and equilibrating back at 50% B for 10 min to end the gradient.
Co-IP MS experiments.
Peptides in each BRP fraction were separated at a flow rate of 200 nl/min over a linear gradient of 100% A to 20% B for 28 min, with a linear increase from 20% B to 60% B for 16 min, and a hold at 90% B for 5 min before returning to 50% B.
Peptides were analysed on an Orbitrap Q Exactive Plus mass spectrometer (Thermo Fisher Scientific) operated in data-dependent mode. Higherenergy collision dissociation tandem mass spectrometry (HCD MS/MS) scans (resolution = 17,500 for iTRAQ and TMT methods) were taken after each MS1 scan (resolution = 70,000) on the top 12 most abundant ions using an AGC target of Letter reSeArCH 3 × 10 6 ions for MS1 and 5 × 10 4 ions for MS2. The isolation widths for MS/MS ions were 1.6 for iTRAQ and TMT methods. The maximum ion fill-time for MS/MS scans was 120 ms, the HCD-normalized collision energy was 29; dynamic exclusion time was set to 20 s, and peptide match and isotope exclusion functions were enabled.
Quantification and identification of peptides and proteins (RAP MS and co-IP MS).
All mass spectra were processed using the Spectrum Mill software package v.6.01 pre-release (Agilent Technologies), which includes modules developed for iTRAQ and TMT6-based quantification. Precursor ion quantification was done using extracted ion chromatograms for each precursor ion. The peak area for the extracted ion chromatogram of each precursor ion subjected to MS/MS was calculated in the intervening high-resolution MS1 scans of the LC-MS/MS runs using narrow windows around each individual member of the isotope cluster. Peak widths in both time and m/z domains were dynamically determined on the basis of mass spectrometry scan resolution, precursor charge and m/z, subject to quality metrics on the relative distribution of the peaks in the isotope cluster versus theoretical. Similar MS/MS spectra acquired on the same precursor m/z in the same dissociation mode with ± 60 s were merged. MS/MS spectra with precursor charge >7 and poor quality MS/MS spectra, which failed the quality filter by having a sequence tag length less than 1, were excluded from searching.
For peptide identification, MS/MS spectra were searched against the human Uniprot database to which a set of common laboratory contaminant proteins was appended. Search parameters included: ESI-QEXACTIVE-HCD scoring parameters, trypsin or Lys-c/trypsin enzyme specificity with a maximum of 2 missed cleavage, 40% minimum matched peak intensity, ± 20 ppm precursor mass tolerance, ± 20 ppm product mass tolerance, and carbamidomethylation of cysteins and isobaric labelling of lysines and N-termini as fixed modifications in the RAP MS (iTRAQ) and the immunoprecipitation mass spectrometry (TMT6) experiments with no fixed modification on lysines or N-termini for the size-exclusion chromatography experiment. Oxidation of methionine, N-terminal acetylation and deamidated (N) were allowed as variable modifications, with a precursor MH + shift range from −18 to 64 Da. Identities interpreted for individual spectra were automatically designated as valid by optimizing score and delta rank1-rank2 score thresholds separately for each precursor charge state in each LC-MS/MS run, while allowing a maximum target-decoy-based false-discovery rate (FDR) of 1.0% at the spectrum level.
In calculating scores at the protein level and reporting the identified proteins, redundancy is addressed in the following manner: the protein score is the sum of the scores of distinct peptides. A distinct peptide is the single highest scoring instance of a peptide detected through an MS/MS spectrum. MS/MS spectra for a particular peptide may have been recorded multiple times (that is, from different precursor charge states, isolated from adjacent BRP fractions or modified by oxidation of Met), but are still counted as a single distinct peptide. When a peptide sequence over eight residues long is contained in multiple protein entries in the sequence database, the proteins are grouped together and the highest scoring one and its accession number are reported. In some cases in which the protein sequences are grouped in this manner, there are distinct peptides that uniquely represent a lower scoring member of the group (isoforms or family members). Each of these instances spawns a subgroup, and multiple subgroups are reported and counted towards the total number of proteins identified. iTRAQ and TMT ratios were obtained from the protein comparisons export table in Spectrum Mill. To obtain iTRAQ or TMT protein ratios, the median was calculated over all of the distinct peptides assigned to a protein subgroup in each replicate. For RAP MS we required each protein to be detected with more than two unique peptides. To enable precise quantification, we limited our analysis to peptides that are uniquely assigned to a specific protein isoform or family member. For co-IP MS we required more than four unique peptides. For statistical analysis, we used the Limma package 35 in R (https://www.r-project.org/) to calculate multiple comparison adjusted P values using a moderated t-test. Native RBMX co-IP and size-excusion chromatograpy. To capture native RBMX complexes, we generated stable HCT116 cell lines that express Flag-RBMX-V5. For co-IP and size-exclusion chromatography experiments, we grew 200 million cells. Cells were collected by scraping culture dishes, washed once with PBS and pelleted by centrifugation at 500g for 5 min. Fresh cell pellets were lysed in 8 ml co-IP lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP40, 0.1% sodium deoxycholate, and Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific)). Lysates were incubated on ice for 30 min and mixed by pipetting every 5-10 min to enhance nuclear lysis. Lysates were cleared by centrifugation at 14,000g for 10 min at 4 °C and insoluble material was removed. We pre-cleared lysates by incubating with 2.5 ml protein G magnetic beads (Thermo Fisher Scientific) for 30 min at 4 °C. Meanwhile, 600 μg Flag M2 antibody (Sigma # F1804) was pre-coupled to 2.5 ml protein G beads for 45 min at room temperature. To non-specifically digest DNA and RNA, we added 500 U benzonase to the cell lysate. Free Flag M2 antibody was removed from magnetic beads and benzonase-treated lysates were added to beads and incubated overnight at 4 °C. The next day, supernatant was removed and beads were washed twice in 50 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.05% NP40, followed by two washes in 50 mM Tris-HCl pH 7.5 and 150 mM NaCl. After the last wash, protein complexes were eluted using 250 μg Flag-peptide in 500 μl of 150 mM NaCl, 25 mM Tris pH 7.5, 0.05% IGEPAL. Elutions were incubated 1 h at 4 °C with agitation. Eluates were separated from beads and filtered using a 0.2-μm membrane filter. Size-exclusion chromatography of the RBMX complex was performed using a Superose 6 Increase 10/300 column (GE Healthcare) equilibrated in 150 mM NaCl, 25 mM Tris pH 7.5, 0.05% IGEPAL. We injected 400 μl of the eluate onto the column at a flow rate of 0.4 ml/min and collected 0.5-ml fractions. Two hundred and fifty microliters of each fraction was subjected to trichloroacetic acid-precipitation to concentrate proteins. Protein content was analysed by western blotting and mass spectrometry.
For mass spectrometry analysis, proteins were reduced, alkylated and denatured at 90 °C for 5 min, spun down and loaded separated by SDS-PAGE. The gel was run in 1× MES SDS-PAGE running buffer at 175 V for 40 min, after which it was stained for 2 h in SimplyBlue Safe Stain (Thermo Fisher Scientific) and destained in water overnight. The gel lane was cut into 4 fractions, diced and destained with 50% ACN, 50% 100mM ammonium bicarbonate. Destaining buffer was removed and gel pieces were dehydrated with 300 μl of ACN. ACN was aspirated once the gel pieces were white. One-and-a-half micrograms of trypsin was added to each of the 4 fractions in 100 μl of 100 mM ammonium bicarbonate (pH 8) and incubated overnight at 37 °C. The supernatant from each fraction was collected into in a fresh tube, and the peptides were extracted from the gel pieces by washing twice with 60% ACN, 0.1% formic acid and collecting the extract in the tube with the initial supernatant. Finally, gel pieces were dehydrated with ACN, which was collected with the rest of the extract. Fractions were then dried using a Speedvac concentrator, reconstituted in 3% ACN and 0.1% formic acid, and desalted on C18 Stage Tips 33 . Eluate from each fraction was transferred to HPLC vials, dried down and reconstituted in 5 μl of 3% ACN, 5% formic acid and run on an EasyNLC 1200 coupled to an Orbitrap Q Exactive Plus mass spectrometer. The previously described method for co-IP MS experiments (see 'Co-IP MS experiments' above) was used for analysis, with the only difference being a normalized collision energy of 25, which is routinely used for label-free peptide analysis.
To extract RNA from size-exclusion chromatography fractions containing the protein complex as well as control fractions we Trizol-extracted the remaining 250 μl of sample, and isolated RNA using Direct-zol columns (Zymo Research). We removed rRNA with the NEBNext rRNA Depletion Kit (New England Biolabs) by following the manufacturer's instructions. Finally, we constructed RNAsequencing libraries using the SMARTer smRNA-Seq Kit (Clontech) by following the manufacturer's instructions. Libraries were sequenced on an Illumina HiSeq 2500 instrument to an average read depth of 15-20 million reads with 50-bp read 1 and 60-bp read 2. We trimmed 5 bp from the beginning of read 1 and 15 bp from the beginning of read 2 before mapping. Reads aligning to rRNA were removed from downstream analysis 36 . Reads were then mapped to hg19 using Bowtie2. Mapping results were restricted to the single best alignment found for any given read. Discordant alignments of paired-end reads were excluded from analysis. Data normalization was performed by scaling coverage values by (1,000,000/total mapped read count). CLIP. The CLIP protocol below is extensively based on three previously published CLIP methods: irCLIP 37 , PAR-CLIP 38 and eCLIP 39 . We constructed the pre-adenylated irCLIP adaptor as previously described 37 . All other oligonucleotides were synthesized as described in the irCLIP protocol, with the exception of reverse transcription primers. We replaced ethyleneglycol spacers with three deoxyuridines and modified the 5′ end of reverse transcription primers to reflect the nucleotide preference of CircLigase II (general structure: /5phos/RNNNNN-6nt-barcode-NNNN NTACCCTTCGCTTCACACACAAG/ideoxyU//ideoxyU//ideoxyU/TACTGAAC CGC).
For each CLIP experiment we grew 20 million HCT116 cells in medium supplemented with 200 μM 4-thiouridine for 8 h. Cells were washed once with PBS and then crosslinked on ice using 0.2 J/cm 2 of 365-nm ultraviolet light in a Stratalinker. Cells were then scraped from culture dishes, washed once with PBS, pelleted by centrifugation at 500g for 5 min and flash-frozen in liquid nitrogen for storage at −80 °C. To prepare cell lysates, pellets were thawed on ice and resuspended in NP40 lysis buffer (50 mM HEPES pH 7.5, 150 mM KCl, 2 mM EDTA, 1% (v/v) NP40, 0.25 mM DTT, complete EDTA-free protease inhibitor cocktail) and incubated on ice for 10 min. We sonicated cell lysates using a Branson Digital Sonifier with a microtip set at 5 W power for a total of 1 min 30 s in intermittent pulses (0.7-s on, 2.3-s off), followed by RNase I (Thermo Fisher Scientific) digestion (0.5 U/μl, 10 min at 23 °C). Subsequently, we added 15 μl/ml Murine RNase Inhibitor (New England Biolabs), followed by DNA digestion (20 U TURBO DNase (2 U/μl; Thermo Fisher Scientific), 2.5 mM MgCl 2 and 0.5 mM CaCl) for 20 min at 37 °C. We incubated samples on ice for 10 min before clearing lysates by centrifugation at 15,000g for 15 min. Insoluble material was removed and total protein concentration was determined by BCA assay. Cell lysates were flash-frozen and stored in batches of 10 mg total protein at −80 °C.
For each immunoprecipitation experiment, lysates (10 mg total protein) were thawed on ice and pre-cleared by incubating with protein A/G magnetic beads (using 30 μl/mg total protein) for 30 min at 4 °C. In the meantime, antibodies (6 μg/mg total protein) were coupled to protein A/G magnetic beads (using 30 μl/mg total protein) at room temperature for 45 min (antibodies used: RBMX, Cell Signaling #14794; ALYREF, Bethyl # A302-892A; PUM1, Bethyl # A302-577A; V5, Abcam # ab27671). We removed unbound antibody and added the pre-cleared lysates to antibody-coupled beads and incubated overnight at 4 °C. The following day, we washed the beads 3 times in IP wash buffer (50 mM HEPES pH 7.5, 300 mM KCl, 0.5% (v/v) NP40, 0.25 mM DTT, complete EDTA-free protease inhibitor cocktail), followed by one wash in FastAP buffer (10 mM Tris-HCl pH 8.0, 5 mM MgCl 2 , 100 mM KCl, 0.02% Triton X-100). Immunopurified protein-RNA complexes were dephosphorylated by resuspending beads in 25 μl FastAP mix (18.5 μl H 2 O, 2.5 μl 10× FastAP buffer (Thermo Fisher Scientific), 2.5 U FastAP enzyme (1 U/μl; Thermo Fisher Scientific), 0.5 μl Murine RNase Inhibitor (New England Biolabs)) and incubating for 20 min at 37 °C. In the meantime, we prepared polynucleotide kinase mix (56 μl H 2 O, 10 μl 10× PNK buffer (New England Biolabs), 1 μl Murine RNase Inhibitor, 7 μl T4 PNK (10 U/μl; New England Biolabs), 1 μl TURBO DNase) and added 75 μl to each 25 μl sample and incubated 20 min at 37 °C. Beads were separated on a magnet and dephosphorylation reaction was removed before washing beads once in RNA ligation buffer without DTT (50mM Tris-HCl pH 7.5, 10mM MgCl 2 ). Next, 3′ ligation was performed by resuspending beads in 20 μl ligation mix (3 μl H 2 O, 2 μl 10× T4 RNA ligation buffer (New England Biolabs), 1 μl DMSO, 1 μl RNase inhibitor, 15 pmoles pre-adenylated 3′ adaptor, 10 μl 50% PEG 8000, 2 μl T4 RNA Ligase 1 High Concentration (New England Biolabs)) using low-retention pipette tips and incubated overnight at 16 °C with agitation. The next day we added 7 μl 4× NuPAGE LDS Sample Buffer (Thermo Fisher Scientific) to ligation reactions and incubated samples for 10 min at 75 °C. Protein-RNA complexes were resolved by SDS-PAGE using NuPAGE 4-12% Bis-Tris-HCl Gels (Thermo Fisher Scientific) at 200 V for 1 h, followed by transfer to a nitrocellulose membrane using the iBlot Dry Blotting System (Thermo Fisher Scientific). Protein-RNA complexes were visualized using the Odyssey Clx infrared imager (LI-COR) and desired complexes were excised from membrane using a clean scalpel. Membrane pieces were immediately subjected to proteinase K treatment by adding 250 μl proteinase K solution (4 mg/ml Proteinase K (New England Biolabs), 100 mM Tris-HCl pH 7.5, 150 mM NaCl, 12.5 mM EDTA, 1% (w/v) SDS) and incubating 1 h at 55 °C. Following proteinase K treatment, RNA was phenol-chloroform extracted using Heavy Phase Lock Gel tubes (5Prime) and purified with the Zymo RNA Clean & Concentrator-5 kit by following the manufacturer's instructions for small and large RNAs. We eluted RNA in 7 μl H 2 O and combined it with 10 pmoles of reverse transcription primer. Samples were heated to 72 °C for 2 min and snap-cooled on ice. Reverse transcription was performed with the SuperScript III kit (Thermo Fisher Scientific) by combining RNA samples with 4 μl 5× First Strand Buffer, 2 μl 0.1M DTT and 6 μl 2mM dNTPs. Samples were incubated at 50 °C for 3 min before adding 1 μl SuperScript III reverse transcription enzyme (200 U/μl) and incubating 1 h at 42 °C. For each reverse transcription reaction, we washed 5 μl MyOne streptavidin C1 beads twice in NT2 buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM MgCl 2 and 0.0005% NP40) and then resuspended the beads in 100 μl NT2 buffer. The resuspended beads were then added to the reverse transcription reaction and the mixture was subsequently incubated for 15 min at room temperature. Beads were washed twice in streptavidin wash buffer (20 mM Tris-HCl pH 7.5, 120 mM NaCl, 2 5mM KCl, 5 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate) and twice in PBS to remove unbound reverse transcription primer. Finally, we resuspended beads in 10 μl of freshly prepared elution buffer (8.25 μl H2O, 1 μl 1 μM elution oligonucleotide (CTGAACCGCTCTTCCGATCT), 0.75 μl of 50 mM MnCl 2 ) and heated the reaction for 5 min at 95 °C, 1 min at 75 °C, followed by a ramp of 0.1 °C per s to 60 °C and holding at 60 °C for 15 min. Once the 60-°C incubation temperature was reached, we prepared CircLigase mix (2 μl H 2 O, 2 μl 10× CircLigase-II buffer (Epicentre), 0.25 μl 50mM MnCl 2 , 4 μl 5M betaine, 1 μl CircLigase-II (Epicentre)) and added 10 μl to each elution without removing beads. We incubated the reaction 2 h at 60 °C. Following incubation, we added 2 reaction volumes Agencourt AMPure XP beads (Beckman Coulter) and 5 reaction volumes isopropanol and incubated 15 min at room temperature. Supernatant was removed and beads were washed once with 80% ethanol (v/v), air-dried and eluted by resuspending dry beads in 25 μl H 2 O, heating for 2 min at 95 °C and isolating supernatants. We used 12 μl cDNA for PCR amplification (program: 2 min at 98 °C followed by 12-15 cycles of 98 °C for 15 s, 65 °C for 30 s and 72 °C for 30 s, followed by a final 20-min extension at 72 °C) in a 50 μl reaction using 25 μl 2× NEBNext Q5 Hot Start HiFi PCR Master Mix (New England Biolabs), 12 μl H 2 O and 1 μl of 25μM PCR1 primer mix containing P3_PCR1 (GCATTCCTGCTGAACCGCTCTTCCGATCT) and P6_PCR1 (TTTCCCCTTGTGTGTGAAGCGAAGGGTA) primers. PCR reactions were subjected to two consecutive rounds of purification using 1.5 volumes of Agencourt AMPure XP beads and two 70% ethanol washes. DNA was eluted in 14 μl H 2 O and subjected to a second PCR amplification (program: 2 min at 98 °C followed by 3-6 cycles of 98 °C for 15 s and 72 °C for 45 s, followed by a final 2-min extension at 72 °C) in a 50 μl reaction using 12 μl purified PCR1, 25 μl 2× NEBNext Q5 Hot Start HiFi PCR Master Mix (New England Biolabs), 12 μl H 2 O and 1 μl of 25 μM PCR2 primer mix containing P3_PCR2 (CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAAC CGCTCTTCCGATCT) and P6_PCR2 (AATGATACGGCGACCACCGAGA TCTACACTCTTTCCCCT TGTGTGTGAAGC GAAGGGTA) primers. Upon completion of PCR amplification, we added 10 μl ExoSAP-IT PCR Product Cleanup Reagent (Thermo Fisher Scientific) and incubated reactions for 15 min at 37 °C. Reactions were purified using 1.1 volumes of Agencourt AMPure XP beads and two 70% ethanol washes, followed by elution of air-dried beads in 10 μl H 2 O. The concentration of final libraries was determined with the Qubit dsDNA HS Assay (Thermo Fisher Scientific) and library sizes were analysed on a High Sensitivity DNA Bioanalyzer Chip (Agilent).
Size-matched input libraries (SM input) 39 were prepared by resolving 1-2% of input lysates by SDS-PAGE using NuPAGE 4-12% Bis-Tris-HCl Gels (Thermo Fisher Scientific) at 200 V for 1 h. SDS-PAGE gels were transferred to a nitrocellulose membrane using the iBlot Dry Blotting System (Thermo Fisher Scientific) and proteins migrating at the molecular weight range of the target protein were excised using a clean scalpel. RNA was released by proteinase K treatment and purified as described in the previous section. We performed end-repair of input RNA by adjusting RNA volume to 19.5 μl with H 2 O and adding 2.5 μl 10× FastAP buffer (Thermo Fisher Scientific), 2.5 U FastAP enzyme (1 U/μl; Thermo Fisher Scientific), 0.5 μl Murine RNase Inhibitor (New England Biolabs)) and incubating for 20 min at 37 °C. In the meantime, we prepared Polynucleotide kinase mix (56 μl H 2 O, 10 μl 10× PNK buffer (New England Biolabs), 1 μl Murine RNase Inhibitor, 7 μl T4 PNK (10 U/μl; New England Biolabs), 1 μl TURBO DNase) and added 75 μl to each 25 μl sample and incubated samples for 20 min at 37 °C. RNA was purified with the Zymo RNA Clean & Concentrator-5 kit using the manufacturer's instructions for small and large RNAs. RNA was eluted in 5 μl H 2 O and combined with 25 μl ligation mix (3 μl 10× T4 RNA ligation buffer (New England Biolabs), 1.5 μl DMSO, 1.5 μl RNase inhibitor, 15 pmoles pre-adenylated 3′ adaptor, 15 μl 50% PEG 8000, 3 μl T4 RNA Ligase 1 High Concentration (New England Biolabs)) using low-retention pipette tips and incubated for 2 h at 23 °C with agitation. Ligation reactions were purified to remove free 3′ adaptor using two consecutive Silane bead purifications. For each reaction, we washed 15 μl Silane beads (Thermo Fisher Scientific) twice in 1 ml RLT buffer (Qiagen), resuspended beads in 90 μl RLT and combined 90 μl beads in RLT with 30 μl ligation reaction. We added 0.7 volumes 100% ethanol and incubated mixtures 10 min at room temperature. Supernatant was removed and beads were washed twice with 70% ethanol before eluting airdried beads in 9 μl H 2 O. We used 7 μl of the eluted RNA for reverse transcription and proceeded with the library preparation as described in the above section. Computational analysis of CLIP data. We sequenced CLIP and corresponding SM input libraries on an Illumina HiSeq 2500 to an average read depth of 30-50 million reads with 52-bp read 1 and 35-bp read 2. The first read includes a 6-nt barcode added during reverse transcription (see 'CLIP' above). After processing to separate samples based on inline barcodes, sequencing reads collected from all CLIP experiments were first mapped to hg19 using TopHat (v.2.0.8) 40 . Reads aligning to rRNA were removed from downstream analysis, as previously described 36 . Duplicate reads were identified and removed using Picard's MarkDuplicates program. Peak calling was performed with the MACS2 41 algorithm to identify genomic coordinates where experimental conditions (protein IP) were significantly enriched for reads relative to size-matched controls (SM input). Peak calling was performed without a shifting model and the band width to compute fragment size was set to 100 bp. Significant peaks are reported with FDR correction of q = 0.05. Significant peaks were further filtered to include only regions with an average minimum depth of two reads in the size-matched control condition. To compile significant results across replicate experiments, we intersected the intervals from the peak calling output of each replicate. Normalized coverage in the intersection peaks was first calculated separately for each replicate as the average depth at a given peak divided by the total number of reads after correcting for the observed duplication rate. The mean of the relative fold change between the two replicates was calculated for each peak and peaks that did not show a twofold or greater change in both replicates were excluded. We report a CLIP signal score for a given peak as the product of enrichment (average fold change) and the peak length (see Supplementary Table 3) . RNA-sequencing and analysis. We performed RNA-sequencing on cells that stably expressed individual sgRNAs targeting the NORAD promoter, with or without doxycycline-induced KRAB-dCas9 expression. We performed at least 2 biological replicate experiments for knockdown and control conditions after 24 h, 48 h and 96 h of KRAB-dCas9 induction. RNA-sequencing libraries were constructed Letter reSeArCH as previously described 36 . Reads were pseudo-aligned to hg19 (ENSEMBL transcripts) using kallisto 42 with an index of either 31 or 21 k-mers. Estimated counts were collapsed across transcripts into genes and differential expression analysis was performed using DESeq2 43 . Genes with an absolute log 2 (fold change) > 1 and FDR < 0.05 were considered as differentially expressed. P values for differential gene expression were corrected using the Benjamini-Hochberg procedure to derive an FDR. Alternative splicing analysis. Percentage spliced in (PSI) for different exons or introns was calculated using SUPPA2 44 based on isoform transcripts per million (TPM) estimates from kallisto for skipping exon, alternative 5′ or 3′ splice sites, mutually exclusive exons, retained intron and alternative first or last exons. Differential PSI was calculated using diffSplice 45 with the parameters '-area 1000-tpm-threshold 5-lower-bound 0.00 -gc' . Events with a change in PSI > 20% and FDR < 0.05 were considered as differentially used. P values across putative splicing events were corrected using the Benjamini-Hochberg procedure to derive an FDR. RNA extraction and RT-qPCR. We extracted RNA from 20,000-50,000 cells per experiment in RLT buffer (Qiagen) using Dynabeads MyOne Silane beads (Thermo Fisher Scientific), treated samples with TURBO DNase (Thermo Fisher Scientific) and cleaned again with Silane beads. We used AffinityScript reverse transcriptase (Agilent Technologies) and random nonamer primers to convert RNA to cDNA. We performed qPCR using SYBR Green I Master Mix (Roche) and calculated differences using the ΔΔC t method versus GAPDH. To achieve power to detect small effects in gene expression, we performed three technical qPCR replicates (from the same cDNA) and took the median value for further analysis. We used the following RT-qPCR primers in this study. RBMX forward primer: CAGTTCGCAGTAGCAGTGGA, RBMX reverse primer: TCGAGGTGGACCTCCATAAC; NORAD forward primer: CTCTGCTGT GGCTGCCC, NORAD reverse primer: GGGTGGGAAAGAGAGGTTCG; PUM2 forward primer: GGGAGCTTCTCACCATTCAATG, PUM2 reverse primer: CCA TGAAAACCCTGTCCAGATC; GAPDH forward primer: AGCCACATCGC TCAGAC AC, GAPDH reverse primer: GCCCAATACGACCAAATCC; MALAT1 forward primer: AGTTCAGTGTTGGGGCAATC, MALAT1 reverse primer: GTTCTTCCGCTCAAATCCTG; TOP1 forward primer: TCGAAGCGG ATTTCCGATTGA, TOP1 reverse primer: CTTTGTGCCGGTGTTCTCGAT. Co-IP western blot. Co-IP experiments were carried out as described above (see 'Co-immunoprecipitation and MS'). The following antibodies were used for immunoprecipitation reactions: RBMX, Cell Signaling #14794, or Santa Cruz Biotechnology # sc-14581; ALYREF, Bethyl # A302-892A; TOP1, Bethyl # A302-589A; CDC5L, Bethyl #A301-681A. Following the last washing step, we resuspended beads in 20 μl Pierce IgG Elution Buffer (Thermo Fisher Scientific) and incubated them for 20 min at room temperature with agitation. We collected supernatants and added 7 μl 4× NuPAGE LDS Sample Buffer (Thermo Fisher Scientific), followed by a 3-min incubation at 95 °C. Proteins were resolved by SDS-PAGE using NuPAGE 4-12% Bis-Tris-HCl Gels (Thermo Fisher Scientific) at 200 V for 1 h, followed by transfer to a nitrocellulose membrane using the iBlot Dry Blotting System (Thermo Fisher Scientific). Proteins larger than 150 kDa in size were resolved on NuPAGE 3-8% Tris-Acetate Gels (Thermo Fisher Scientific). Western blots were performed using the iBind Western System (Thermo Fisher Scientific). For protein detection, we used the following primary antibodies: RBMX, Cell Signaling #14794, or Santa Cruz Biotechnology #sc-14581; ALYREF, Santa Cruz Biotechnology #sc-32311; TOP1, Santa Cruz Biotechnology # sc-32736; CDC5L, Santa Cruz Biotechnology #sc-81220. We used the following secondary antibodies:
For visualization of bands, we used the Odyssey Clx infrared imager system (LI-COR). NORAD conservation analysis. We tested for conservation of NORAD transcription across 11 mammalian species: human, chimpanzee, gorilla, orangutan, rhesus macaque, mouse, rat, ferret, dog, cow and armadillo. Because expression of NORAD is highest in human brain 46 we checked for transcription in brain tissue from these 11 species. Raw RNA-sequencing read data were downloaded from previous studies [47] [48] [49] and mapped to respective genomes using STAR v.2.5.2a 50 , with gene annotations from Ensembl Release 91 51 as a reference guide. For each RNAsequencing library, a de novo transcriptome was made using Stringtie v.1.3.3b 52 , using default parameters. Samples from the same species were then merged using the stringtie-merge option. To find reciprocal best hits, we used nucleotide BLAST with default parameters. Multiple sequence alignment was created using MAFFT 53 with gap penalty reduced to 1.0. Subcellular fractionation. We prepared nuclear and cytoplasmic extracts from freshly grown HCT116 cells using the PARIS Kit (Thermo Fisher Scientific) by following the manufacturer's instructions. We used ~10 million cells for each fractionation experiment and analysed extracts by western blot or RT-qPCR as described in the corresponding sections.
smRNA FISH. smRNA FISH experiments were performed using the ViewRNA Cell Plus Assay Kit (Thermo Fisher Scientific) and following the manufacturer's instructions. We grew 50,000 cells in black 12-well glass-bottom plates (Cellvis) for 24 h. To induce DNA damage, we supplemented culture medium with doxorubicin (1 μM) or camptothecin (200 nM) for 12 h. We washed cells once with PBS before fixation. Cells were then fixed and permeabilized simultaneously in fixation/permeabilization buffer for 30 min at room temperature on a rotating plate. After three brief washes in PBS, we incubated cells with the appropriate probe set diluted 1:100 in probe set diluent for 2 h at 40 °C, then with preamplifier mix at 40 °C for 70 min, followed by amplifier mix at 40 °C for 70 min, and finally label probe mix at 40 °C for 60 min. For nuclei staining, we incubated the cells for 2 min at room temperature with 1× ViewRNA Cell Plus DAPI in PBS. Cells were then washed three times in PBS and then incubated with Alexa Fluor 647 phalliodin (Cell Signaling Technology) diluted 1:20 in PBS for 15 min at room temperature for staining of actin filaments. After a final set of washes, we covered cells with ProLong Gold Anti-Fade Reagent (Cell Signaling Technology) and stored the plates at 4 °C until imaging. The probe sets and corresponding fluorophores were type 1 -NORAD and MALAT1 (Alexa Fluor 546) and type 4 -GAPDH (Alexa Fluor 488). Confocal microscopy was performed using a Nikon Eclipse Ti1 with Andor Yokogawa Spinning Disk Revolution WD system. Quantification of RNA FISH images. For three-dimensional FISH image analysis, Z-stacks were exported such that the top and bottom slices were the beginning and end of DAPI signal in the z direction. Quantification of FISH foci was done with FISH-quant 54 in MATLAB (version R2017b) following the software's instructions for mature mRNA quantification. Before spot detection, a dual Gaussian filter was applied to the images in FISH-quant using the default settings. The outline of nuclei and cells were determined automatically with the Cell Segmentation Tool in FISHquant and a modified version of a Cell Profiler pipeline provided in the FISH-quant repository. In Cell Profiler (v.2.2.0) 55 , nuclear boundaries were determined by the Otsu method guided by DAPI staining. Identified nuclei were then used as seeds to identify the boundaries of cells by the watershed method aided with the phalloidin stain. For all probes, the local maximum strategy of spot pre-detection was used. Settings for thresholding pre-detected spots were optimized for each probe separately to account for differences in signal intensity. In situ proximity ligation assay. In situ proximity ligation assay (PLA) was performed using the Duolink PLA platform (Sigma) and following the manufacturer's instructions. Cells were plated in black, glass-bottom 96-well plates the day before the experiment and allowed to grow overnight at 37 °C. Cells were fixed with 4% paraformaldehyde in PBS for 15 min at room temperature, washed three times in PBS and then permeabilized with 0.5% Triton X-100 in PBS for 15 min at room temperature. Cells were blocked for 1 h at 37 °C in a humidified chamber using the Duolink blocking solution, and subsequently stained with primary antibodies diluted 1:250 in Duolink antibody diluent for 1 h at room temperature. DuoLink PLA probes (Rabbit PLUS and Mouse MINUS) were added for 1 h at 37 °C. The ligation and subsequent amplification steps were performed for 30 min and 100 min, respectively, at 37 °C. Upon completion of the assay, cells were overlaid with Duolink mounting medium with DAPI. Two sets of primary antibody pairs were used: rabbit anti-RBMX (Cell Signaling Technologies #14794) was paired with mouse anti-TOP1 (Thermo Fisher Scientific #435900); mouse anti-Flag (Cell Signaling Technologies #8146S) (targeting Flag-RBMX) was paired with rabbit anti-TOP1 (Bethyl #A302-589A). Quantification of PLA images. For PLA signal quantification we used Cell Profiler 3.0.0. Separate maximum intensity projections for each channel were exported. Nuclei and PLA-signal segmentation was performed using the minimal cross entropy thresholding method. We applied default settings for nuclei segmentation, whereas the PLA signal detection required more stringent thresholding to distinguish individual spots within clusters. A size filter was applied to exclude overlapping nuclei from the analysis. The total nuclear PLA spot count was normalized to the total nuclear area for each cell. Immunostaining of cultured cells for anaphase nuclei imaging. We induced knockdown in CRISPRi cells with stably integrated sgRNAs by supplementing cell culture medium with 0.5 μg/ml doxycycline for 48 h. Cells were then trypsinized and plated in multi-well glass-bottom plates (Cellvis), again supplementing culture medium with doxycycline in knockdown cells, and grown for an additional 24 h. We removed culture medium, rinsed each well in PBS and fixed cells in 4% paraformaldehyde (PFA) for 10 min at room temperature. All subsequent manipulation steps were carried out in a humidified chamber. PFA was removed, cells were washed twice in PBS and permeabilized by incubating with PBS + 0.1% Triton X-100 for 10 min at room temperature. Following permeabilization, we blocked cells in PBS containing 4% BSA (Roche), 10% goat serum (Sigma Aldrich) and 0.1% Triton X-100 for 30 min at room temperature. Primary antibodies (anti-α-tubulin−FITC antibody, Sigma Aldrich #F2168 (1:1,000); anti-centromere antibodies, Antibodies Incorporated # 15-234-0001 (1:200)) were diluted in blocking buffer (PBS containing 4% BSA (Roche), 10% goat serum (Sigma Aldrich) and Table 6 ); 89,352, 88,529 and 84,340 events were analysed at 24, 48 and 96 h, respectively. Only six events were consistent between two time points and none were consistent between all three time points b, RT-qPCR measurements of NORAD 5′ fragment (light grey) and fulllength NORAD (dark grey) in rescue experiments using full-length and 5′-truncated NORAD rescue constructs. Measurements correspond to cells used in cell-cycle analysis. Quantification relative to GAPDH. Values are mean ± standard deviation (n = 5 or 6). c, RT-qPCR measurements of RBMX CRISPRi knockdown. Quantification relative to GAPDH. Values are mean ± standard deviation (n = 5). d, RT-qPCR measurements of TOP1 RNA interference knockdown. Quantification relative to GAPDH. Values are mean ± standard deviation (TOP1 siRNA, n = 6; control siRNA, n = 5). e, Representative fluorescence-activated cell sorting histograms measuring EdU incorporation and DNA content in RBMX and NORAD CRISPRi knockdown and NORAD rescue cells. Percentage of cells in each cell-cycle phase is indicated. f, As in e, but for TOP1 RNA interference knockdown cells. 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability Sequencing data associated with Fig. 2, 3 , and Extended Data Fig. 3 , 4, 5 is available at the Gene Expression Omnibus under the accession number GSE114953.
